Zambon SpA

Privately held: no public share price

Assets

(3 total)
3Total Assets
2Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Approved
dopamine precursorSmall molecule
Parkinson's Disease
Safinamide(Xadago)
Approved
MAO-BSmall molecule
Parkinson's Disease
Voriconazole (ZP-059)No recent activity
Phase 1
fungal CYP51 / lanosterol 14-alpha-demethylaseSmall molecule
AsthmaAllergic Bronchopulmonary Aspergillosis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.